AbbVie Inc. (ABBV)
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
ABBV eyes a strong Q1 performance as neuroscience sales, led by Botox and Vraylar, are set to jump 22%, with newer drugs helping offset declines in legacy treatments.
Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
ABBV edges out PFE as Skyrizi and Rinvoq fuel strong growth, offsetting Humira losses and positioning the drugmaker for sustained expansion.
AbbVie: Fairly Valued And Positioned For Growth
AbbVie Inc. (ABBV) is positioned for growth recovery both in terms of profits and dividends. Upcoming FQ1 2026 earnings are expected to show robust growth: EPS of $2.93 (+19.1% YoY) and revenue of $14.72B (+10.3% YoY). Dividend growth appears to be recovering, with the latest annual increase at 5.48%, signaling potential stabilization after recent deceleration.
3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
The calendar says it's spring, but investors can't be blamed for feeling like it's Groundhog Day: The economic issues impacting portfolios continue to persist this year. Just after a ceasefire between the United States and Iran was announced, providing an impactful market tailwind, investors are getting the latest inflation readings, which appear to be making an unwanted comeback.
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)
AbbVie Inc. is forecast to deliver robust Q1 performance, with revenues of ~$14.7bn, up ~8% year-on-year. Immunology remains ABBV's core driver, with Skyrizi and Rinvoq offsetting Humira's LOE, but patent cliffs loom in the 2030s. Oncology bets are significant but carry execution risk; pipeline diversification is limited beyond ADCs and select late-stage assets.
AbbVie: Upside Potential And Dividends With Competent Portfolio Renewal
AbbVie (ABBV) executes an excellent portfolio renewal beyond Humira's patent expiry, with Skyrizi and Rinvoq delivering robust double-digit revenue gains. Their efficient R&D and successful M&A activities have enabled a resilient pipeline, with these developments contributing to their renewed, accelerated profitable growth trends over the next few years. Despite the lowered FY2026 EPS guidance to $14.06, their underlying adjusted figures remain stable, with near-term headwinds merely attributed to lumpy IPR&D and milestone expenses.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie: Lowered Guidance Is Just Noise - Reiterate Buy
AbbVie remains a buy, as recent EPS guidance reductions are driven by normal IPR&D and milestone expenses, not operational weakness. Their Q4 showed robust 10% revenue growth and a 38.3% adjusted operating margin, with bottom-line growth outpacing sales. Pipeline strength is evident with positive Skyrizi and ABBV-295 trial results, offsetting competitive and regulatory headwinds.
AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns
AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204.
AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, AbbVie (ABBV) closed at $206.69, indicating a -1.03% shift from the previous trading day.
AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
AbbVie remains a 'Buy,' with valuation and forward EPS growth supporting the thesis despite recent sector weakness and an 8% YTD decline. Q4 results exceeded expectations: non-GAAP EPS of $2.71 and revenue up 10% YoY, driven by Skyrizi and Rinvoq offsetting Humira declines. Management guides for FY 2026 adjusted EPS of $14.37–$14.57 and forecasts robust free cash flow ($18.5 billion), underpinning the high dividend yield.
High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories.
